StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.30−0.08 (-5.80%)

Close on Nov 19, 2026Market cap $181.40MP/E –Yield –

Inhibikase Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Inhibikase Therapeutics

Inhibikase Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Inhibikase Therapeutics figures

See a number that looks wrong?